Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study
| العنوان: | Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study |
|---|---|
| المؤلفون: | Paul D. Shilling, John I. Nurnberger, Michael McCarthy, Martin Alda, Megan Ritchey, Wade H. Berrettini, Vigdis Elin Giever Syrstad, Cynthia V. Calkin, Peter P. Zandi, Gloria Harrington, Fernando S. Goes, William Coryell, Elliot S. Gershon, Yokesh Balaraman, Toyomi Goto, Elizabeth Karberg, Abesh Kumar Bhattacharjee, Joseph R. Calabrese, Bruce Tarwater, Caroline M. Nievergelt, Helle K. Schoeyen, Kelly A. Ryan, John R. Kelsoe, Joanna M. Biernacka, Julie Garnham, Masoud Kamali, Kara Glazer, Falk W. Lohoff, Francis M. Mondimore, Gunnar Morken, Yian Lin, Ney Alliey-Rodriguez, Mark A. Frye, Nicole Frazier, Petter Jakobsen, Marth Shaw, Ole A. Andreassen, Melvin G. McInnis, Adam X. Maihofer, Martha Schinagle, Emma K. Stapp, Susan G. Leckband, Keming Gao, Amit Anand, Carrie Fisher, Marisa Kelly, Claire Slaney, Andrea Stautland, Carla Conroy, Ketil J. Oedegaard, Anna DeModena, Nicole D'Arcangelo, Holli Bertram |
| المصدر: | Bipolar Disorders |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, Bipolar Disorder, Lithium (medication), business.industry, Lithium, medicine.disease, Treatment failure, First line treatment, Psychiatry and Mental health, Pharmacotherapy, Treatment Outcome, Prospective trial, Pharmacogenetics, Internal medicine, Partial response, Pharmacogenomics, medicine, Lithium Compounds, Humans, Bipolar disorder, Prospective Studies, business, Biological Psychiatry, medicine.drug |
| الوصف: | Background Lithium is regarded as a first-line treatment for bipolar disorder (BD), but partial response and non-response commonly occurs. There exists a need to identify lithium non-responders prior to initiating treatment. The Pharmacogenomics of Bipolar Disorder (PGBD) Study was designed to identify predictors of lithium response. Methods The PGBD Study was an eleven site prospective trial of lithium treatment in bipolar I disorder. Subjects were stabilized on lithium monotherapy over 4 months and gradually discontinued from all other psychotropic medications. After ensuring a sustained clinical remission (defined by a score of ≤3 on the CGI for 4 weeks) had been achieved, subjects were followed for up to 2 years to monitor clinical response. Cox proportional hazard models were used to examine the relationship between clinical measures and time until failure to remit or relapse. Results A total of 345 individuals were enrolled into the study and included in the analysis. Of these, 101 subjects failed to remit or relapsed, 88 achieved remission and continued to study completion, and 156 were terminated from the study for other reasons. Significant clinical predictors of treatment failure (p < 0.05) included baseline anxiety symptoms, functional impairments, negative life events and lifetime clinical features such as a history of migraine, suicidal ideation/attempts, and mixed episodes, as well as a chronic course of illness. Conclusions In this PGBD Study of lithium response, several clinical features were found to be associated with failure to respond to lithium. Future validation is needed to confirm these clinical predictors of treatment failure and their use clinically to distinguish who will do well on lithium before starting pharmacotherapy. publishedVersion |
| وصف الملف: | application/pdf |
| تدمد: | 1399-5618 1398-5647 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55d7bb7e93e92fc2550142370e33ba30Test https://pubmed.ncbi.nlm.nih.gov/33797828Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....55d7bb7e93e92fc2550142370e33ba30 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13995618 13985647 |
|---|